EPIDIOLEX® (cannabidiol) oral solution: Now FDA Approved, Pending Rescheduling
Click here to see Press Release.

Sign up here to receive EPIDIOLEX information and availability updates.


Our vision is to be the global leader in prescription cannabinoid medicines, developing and providing pharmaceutical products which address clear unmet needs.

Justin Gover
Chief Executive Officer

Spotlight News

May 16, 2018
Greenwich Biosciences’ Spotlight highlights various aspects of our scientific research and cannabinoid clinical development program. We bring forward the voices of our dedicated employees and members of the medical, caregiver and advocacy community who make an invaluable contribution to our efforts.
Apr 25, 2018
In late 2017, when the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for an investigational cannabidiol (CBD) for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) and Dravet syndrome, it marked a significant milestone for Greenwich Biosciences. 

Recent News

father and daughter
Jun 25, 2018
London, UK, Carlsbad, CA, June 25, 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S.

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved


CBD Oral Solution
Dravet Syndrome
2 Phase 3 Trials
Completed Phase 3
CBD Oral Solution
Lennox-Gastaut Syndrome
Completed Phase 3
CBD Oral Solution
Tuberous Sclerosis Complex
Phase 3 Trial Recruiting
Completed Phase 2
CBD Oral Solution
Infantile Spasms
Phase 2 Trial Underway
Phase 2
Neonatal Hypoxic-ischemic Encephalopathy